Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel ...

Unlike traditional continuous glucose monitors that measure glucose levels in interstitial fluid, the CBGM measures glucose directly from blood, aiming to provide real-time readings without the ...

“2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company. As we move into the ...

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

The Farapulse system in full with the Farawave ablation catheter, Farastar ablation generator and Faradrive steerable sheath. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX ...

GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company's ...

The Carillon system is made of nitinol. [Image courtesy of Cardiac Dimensions] Cardiac Dimensions announced today that it closed an oversubscribed Series E financing round worth $53 million.

(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...